Status:
COMPLETED
Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients
Lead Sponsor:
University Hospitals Coventry and Warwickshire NHS Trust
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Measurement of plasma chromogranin A remains the most commonly used biomarkers for both screening and monitoring of patients with gastro-entero-pancreatic neuroendocrine tumours (GEP-NET), despite sev...
Eligibility Criteria
Inclusion
- GEP-NET patients:
- Confirmed diagnosis of NET
- Aged 18 or over
- Able to provide written informed consent
- Able to commit to 3 visits within a 4 week period
- Able to fast overnight
- Able to adequately read/write/speak English
- CONTROLS:
- No known diagnosis of NET
- Aged 18 or over
- Able to provide written informed consent
- Able to commit to 3 visits within a 4 week period
- Able to fast overnight
- Able to adequately read/write/speak English
Exclusion
- \- GEP-NET patients
- No confirmed diagnosis of a NET
- Under the age of 18
- Unable to provide written informed consent
- Pregnant women
- Any patients who are un well on the day of their routine appointment
- Unable to fast overnight
- Unable to adequately read/write/speak English
- CONTROLS
- Confirmed diagnosis of NET
- Under the age of 18
- Unable to provide written informed consent
- Pregnant women
- Any patients who are un well on the day
- Unable to fast overnight
- Unable to adequately read/write/speak English
Key Trial Info
Start Date :
February 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 10 2022
Estimated Enrollment :
346 Patients enrolled
Trial Details
Trial ID
NCT03288402
Start Date
February 1 2017
End Date
February 10 2022
Last Update
June 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The ARDEN NET Centre, ENETS Centre of Excellence
Coventry, United Kingdom, CV2 2DX